Incyte to Report Second Quarter Financial Results
The schedule for the press release and conference call/webcast is as follows:
- Q2 2025 Press Release: July 29, 2025 at 7:00 a.m. ET
- Q2 2025 Conference Call: July 29, 2025 at 8:00 a.m. ET
- Domestic Dial-In Number: 877-407-3042
- International Dial-In Number: 201-389-0864
- Conference ID Number: 13754581
If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the
The live webcast with slides can be accessed at and will be available for replay for ninety days.
About Incyte
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in
For additional information on Incyte, please visit or follow us on social media: , , , , .
View source version on businesswire.com:
Incyte Contacts
Media
[email protected]
Investors
[email protected]
Source: Incyte